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Abstract
The	major	histocompatibility	complex	class	I	and	class	II	human	leukocyte	antigens	
(HLA)	play	a	central	role	in	adaptive	immunity	but	are	also	the	dominant	polymorphic	
proteins	targeted	in	allograft	rejection.	Sensitized	patients	with	high	levels	of	panel-	
reactive	anti-	HLA	antibody	 (PRA)	 are	 at	 risk	of	 early	 allograft	 injury,	 rejection,	 re-
duced	 allograft	 survival	 and	 often	 experience	 prolonged	 waiting	 times	 prior	 to	
transplantation.	Xenotransplantation,	using	genetically	modified	porcine	organs,	of-
fers	a	unique	source	of	donor	organs	for	these	highly	sensitized	patients	if	the	anti-	
HLA	 antibody,	 which	 places	 the	 allograft	 at	 risk,	 does	 not	 also	 enhance	 anti-	pig	
antibody	 reactivity	 responsible	 for	 xenograft	 rejection.	 Recent	 improvements	 in	
xenotransplantation	efficacy	have	occurred	due	 to	 improved	 immune	suppression,	
identification	of	additional	xenogeneic	glycans,	and	continued	improvements	in	donor	
pig	genetic	modification.	Genetically	engineered	pig	cells,	devoid	of	the	known	xeno-
geneic	glycans,	minimize	human	antibody	reactivity	in	90%	of	human	serum	samples.	
For	waitlisted	patients,	early	comparisons	of	patient	PRA	and	anti-	pig	antibody	reac-
tivity	found	no	correlation	suggesting	that	patients	with	high	PRA	levels	were	not	at	
increased	risk	of	xenograft	rejection.	Subsequent	studies	have	found	that	some,	but	
not	all,	highly	sensitized	patients	express	anti-	HLA	class	I	antibody	which	cross-	reacts	
with	swine	leukocyte	antigen	(SLA)	class	I	proteins.	Recent	detailed	antigen-	specific	
analysis	 suggests	 that	 porcine-	specific	 anti-	SLA	 antibody	 from	 sensitized	 patients	
binds	cross-	reactive	groups	present	in	a	limited	subset	of	HLA	antigens.	This	suggests	
that	 using	 modern	 genetic	 methods,	 a	 program	 to	 eliminate	 specific	 SLA	 alleles	
through donor genetic engineering or stringent donor selection is possible to mini-
mize	recipient	antibody	reactivity	even	for	highly	sensitized	individuals.
K E Y W O R D S
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1  | INTRODUC TION
The	 classical	major	 histocompatibility	 complex	 (MHC)	molecules	
are highly polymorphic glycoproteins which play a central role in 
adaptive immunity by capturing and presenting peptide antigens 
to	the	T-	cell	receptor	(TCR)	expressed	on	T	lymphocytes.1	There	
are	 two	major	 classes	of	human	MHC,	 the	human	 leukocyte	an-
tigens	 (HLA)	class	 I	and	class	 II	proteins.	The	class	 I	proteins	are	
expressed widely on nucleated cells and present antigen in asso-
ciation	with	beta-	2-	microglobin	to	TCR	on	CD8	T	cells.	The	three	
major	class	I	loci,	A	B,	and	C,	account	for	over	12	000	alleles.	The	
HLA	class	II	proteins	are	expressed	on	antigen-	presenting	cells	(B	
cells,	dendritic	cells,	and	macrophages)	and	present	peptide	anti-
gen	to	CD4	T	cells.	There	are	fewer	class	II	genes	with	4802	listed	
in	 the	 International	 Immunogenetics	 and	 HLA	 database	 (IMGT/
HLA).2
Because	of	a	high	level	of	polymeric	amino	acid	variation,	human	
class	I	and	II	proteins	have	long	been	recognized	as	the	major	trans-
plantation	antigens	which	stimulate	allograft	organ	rejection.3	The	
majority	of	amino	acid	variation	occurs	in	the	regions	of	the	proteins	
which	form	the	peptide	binding	site	for	antigen	presentation.4	This	
polymorphism	allows	for	a	high	diversity	of	peptide	presentation,	but	
also	creates	antigenic	diversity	between	individuals.	Sensitization	to	
HLA	gene	products	occurs	 as	 an	 induced	 immune	 response	when	
patients	are	challenged	through	blood	transfusions,	pregnancies,	or	
failed	organ	 transplants.	For	patients	 awaiting	kidney	 transplanta-
tion,	sensitization	is	commonly	due	to	the	relatively	high	frequency	
of	dialysis-	related	blood	transfusion.	Highly	sensitized	patients	 re-
main longer on the transplant waiting list and when they are trans-
planted	are	at	higher	risk	of	early	graft	injury,	rejection,	and	reduced	
graft	survival.5,6
The	efficacy	of	preclinical	xenotransplantation	has	recently	im-
proved	 with	 heterotopic	 pig-	to-	nonhuman	 primate	 (NHP)	 cardiac	
xenotransplantation7-10	 now	measured	 in	 years,	 encouraging	 early	
success in orthotopic cardiac transplantation11-13 and major im-
provements	 in	 life-	supporting	 renal	 xenotransplantation14,15 with 
recipient	survival	beyond	1	year.	These	results	are	spurring	renewed	
interest in moving toward clinical xenotransplantation. In addition 
to	 increasing	 the	overall	 supply	of	organs	 for	 transplantation,	 suc-
cessful	 clinical	 xenotransplantation	 may	 be	 particularly	 helpful	 to	
sensitized	patients	 if	 increased	 antibody	 reactivity	 to	 human	HLA	
antigens does not also increase antibody reactivity to porcine donor 
organs.	 This	 review	 summarizes	 the	 literature	 which	 has	 exam-
ined	 the	potential	 of	 anti-	HLA	antibody	 in	 allo-	sensitized	patients	
to	cross-	react	with	porcine	cells.	The	body	of	evidence	from	these	
studies	suggests	that,	at	the	current	level	of	sensitivity,	most	trans-
plant	 patients	 and	 patients	with	moderate	 allo-	sensitization	 show	
minimal human antibody reactivity to pig cells when these cells 
lack	the	three	known	xenogeneic	antigens	galactose	a	1,3	galactose	
(aGal),	 N-	glycolylneuraminic	 acid	 (Neu5Gc)	 modified	 glycans	 and	
porcine	 B4GALNT2-	dependent	 SDa	 glycans.16,17 For highly sen-
sitized	patients,	 there	 is	often,	but	not	always,	an	 increase	 in	anti-	
pig	antibody	reactivity	which	could	affect	xenotransplant	survival.	
Recent	analysis	suggests	that	stringent	patient	cross-	matching	and/
or	elimination	of	a	limited	set	of	specific	porcine	class	I	swine	leuko-
cyte	antigens	 (SLA)	 alleles	 can	 further	minimize	anti-	pig	 reactivity	
such	 that	 future	 clinical	 xenotransplantation	 may	 be	 appropriate	
even	for	highly	sensitized	patients.
2  | DETEC TING HL A SENSITIZ ATION AND 
ALLOTR ANSPL ANTATION
Early clinical transplantation programs screened donor and recipi-
ents	 for	matching	blood	type	but	did	not	 routinely	screen	 for	evi-
dence	of	sensitization	to	other	donor	antigens.	In	a	landmark	study,18 
Patel	and	Terasaki	demonstrated	that	a	complement-	dependent	cy-
totoxicity	(CDC)	test	of	patients	serum	against	a	panel	of	unrelated	
donor	 lymphocytes	 could	 be	 used	 to	 detect	 allo-	sensitization.	 By	
analyzing	248	renal	transplants,	they	showed	that	80%	of	recipients	
with	a	positive	panel-	reactive	antibody	 (PRA)	had	 immediate	graft	
failure	compared	to	only	2.4%	of	recipients	without	a	donor-	specific	
antibody	 cross-	match.	 Adoption	 of	 this	 assay	 almost	 completely	
eliminated	 hyperacute	 antibody-	mediated	 allograft	 rejection	 and	
quickly	became	the	early	gold	standard	for	detecting	donor-	specific	
HLA	antibodies.
Technical	 improvements	 to	 the	 CDC	 assay	 and	 development	
of	new	assays	using	flow	cytometry,19	solid-	phase	ELISA	or	single	
antigen bead assays20	 based	on	HLA	proteins	 and	peptides	 have	
further	 increased	 sensitivity	 and	 specificity	 for	 detecting	 allo-	
sensitization.21	 This	 led	 to	 the	 current	 calculated	 panel-	reactive	
antibody	 (CPRA)	score	used	 in	kidney	allocation	which	 is	an	esti-
mate	of	the	percent	of	deceased	donors	that	would	be	cross-	match	
incompatible	based	on	the	identification	of	unacceptable	HLA	an-
tigens	 and	 their	 frequency	 in	 a	 large	 regional	 pool	 of	 donors.	 In	
the	Organ	Procurement	and	Transplantation	Network	(OPTN)	da-
tabase,	there	are	currently	95	562	kidney	transplant	candidates	on	
the	waiting	list	(Figure	1).	Of	these	40%	have	some	degree	of	sensi-
tization	with	CPRA	>1.	About	31%	of	sensitized	patients,	however,	
have	a	CPRA	>80%.
These	advanced	anti-	HLA	antibody	detection	methods	have	im-
proved donor recipient matching and provided more detailed moni-
toring	and	analysis	of	the	immune	response	in	transplant	recipients.	
Most	 highly	 sensitized	 patients	 produce	 anti-	HLA	 antibody	which	
reacts	with	shared	public	epitopes	present	on	a	variety	of	HLA	al-
leles.	It	is	now	clear	that	these	antibodies	are	binding	defined	pep-
tide	 sequences	 and	 topographies	 shared	 between	 different	 HLA	
proteins.	There	 is	 sequence	homology	between	human	and	 swine	
leukocyte	antigens	(SLA),	and	some	anti-	HLA	monoclonal	antibodies	
do	cross-	react	with	SLA.22	So	the	question	arises,	do	patients	sen-
sitized	to	HLA	antigens	also	show	increased	antibody	reactivity	to	
porcine	cells?	If	this	is	the	case,	then	xenotransplantation	may	not	be	
an	advantageous	source	of	organs	for	highly	sensitized	patients,	but,	
if	there	is	not	a	concomitant	increase	in	anti-	pig	antibody	in	patients	
with	HLA	sensitization,	then	xenotransplantation	may	be	an	import-
ant	alternative	source	of	organs	for	these	patients.
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3  | STR ATEGIES FOR DETEC TING 
HL A CROSS-  RE AC TIVIT Y FOR 
XENOTR ANSPL ANTATION
Xenograft	 rejection	 is	 recognized	 as	 an	 overwhelmingly	 antibody	
driven	 process	 due	 to	 the	 very	 high	 level	 of	 anti-	pig	 antibodies	
naturally	 present	 in	 human	 serum.	 The	 bulk	 of	 these	 antibodies	
are	 not	 directed	 to	 swine	 SLA	 but	 bind	 to	 the	 major	 xenogeneic	
glycan	 galactose	 alpha	 1,3	 galactose	 (αGal).23	With	 the	 advent	 of	
pigs	 engineered	 with	 a	 GGTA-	1	 mutation,24,25 which eliminates 
αGal	expression	(GTKO),	the	impact	of	other	antibodies	directed	to	
non-	Gal	antigen	including	SLA-	I	has	become	more	apparent.16,26-28 
There	have	been	a	limited	number	of	studies	designed	to	determine	
whether	sensitization	to	HLA	results	in	enhanced	antibody	reactiv-
ity to pig cells.16,29-37	 These	 studies	 have	 been	 performed	 over	 a	
20-	year	period	and	as	such	span	a	range	of	technological	develop-
ments	both	for	defining	allo-	sensitization	and	in	technologies	to	de-
tect	xenoreactive	antibody.	In	this	review,	the	studies	are	presented	
as	four	basic	research	strategies	based	on	the	use	of	whole	serum	
(type	I),	anti-	Gal	depleted	serum	(Type	II)	and	anti-	Gal	and	anti-	Class	
I	depleted	serum	(type	III).	The	fourth	study	type	largely	used	whole	
human serum but measured patient antibody reactivity to geneti-
cally	modified	porcine	cells	lacking	the	three	known	xenogeneic	gly-
cans	 (αGal,	 Neu5Gc	modified	 glycans	 and	 SDa)	 with	 and	without	
deletion	of	SLA-	I	genes.
3.1 | Type I studies
The	 earliest	 study29 screened 105 waitlisted patient sera against 
αGal expressing porcine peripheral blood lymphocytes representing 
the	three	known	haplotypes	for	NIH	miniature	swine.	They	demon-
strated	that	patient	PRA,	measured	by	CDC,	was	not	correlated	to	
the	 level	of	anti-	pig	antibody	titer.	Moreover,	most	human	anti-	pig	
reactivity	 was	 IgM	whereas	 anti-	HLA	was	 dominantly	 IgG.	Wong	
et al35	extended	this	type	of	analysis	by	comparing	antibody	binding	
of	sensitized	patient	sera	to	αGal-	positive	wild-	type	(WT)	and	GTKO	
miniature	 swine	 peripheral	 blood	 mononuclear	 cells	 (PBMNCs).	
There	was	a	clear	reduction	in	antibody	reactivity	and	CDC	to	GTKO	
cells,	consistent	with	the	loss	of	the	αGal	antigen,	but	no	correlation	
between	 antibody	 reactivity	 or	 cytotoxicity	 to	PRA	 level	 from	88	
waitlisted	patient	sera	for	either	WT	or	GTKO	cell	type.	Cytotoxicity	
to	 porcine	 GTKO	 cells	 was	 mainly	 mediated	 by	 IgM	 antibody	 in	
contrast	 to	 anti-	human	 cytotoxicity	which	was	predominantly	 IgG	
dependent.	Similar	results	were	found	analyzing	WT	and	GTKO	pig	
cells	from	animals	with	a	commercial	agricultural	background	(Large/
White,	 Landrace,	Duroc).36	A	 recent	 study	using	 cells	 from	GTKO	
and	 GTKO/CMAHKO	 pigs	 expressing	 human	 CD46	 also	 failed	 to	
find	enhanced	antibody	reactivity	in	10	highly	sensitized	wait	listed	
serum samples.37	Collectively	these	studies	concluded	that	patients	
with	high	PRA	sera	do	not	necessarily	produce	correspondingly	high	
titer	 of	 anti-	pig	 antibody	 or	 a	 high	 levels	 of	 anti-	pig	 cytotoxicity.	
Thus,	allo-	sensitized	patients	would	not	be	at	greater	risk	of	xeno-
graft	rejection.
3.2 | Type II and III studies
Type	II	studies	used	porcine	red	blood	cells	(RBCs),	which	do	not	ex-
press	SLA-	I,	to	deplete	patient	serum	of	anti-	Gal	antibody	and	type	
III	 studies	used	a	combination	of	porcine	RBCs	and	porcine	plate-
lets,	which	do	express	SLA-	I,	to	deplete	both	anti-	Gal	and	anti-	SLA	
antibody.	When	only	anti-	Gal	antibody	is	depleted,	Oostingh	et	al33 
found	that	some	highly	sensitized	patient	serum	shows	a	correlation	
between	serum	PRA	and	anti-	pig	antibody	reactivity.	This	study	of	
82	patient	serum	samples	used	both	CDC	and	more	sensitive	Flow	
Cross	match	with	class	I	beads	to	define	PRA	levels,	identifying	12	
samples	with	0%	PRA,	50	samples	with	PRA	from	11%	to	84%	and	
20	 samples	 with	 PRA	 >84%.	 Peripheral	 blood	 mononuclear	 cells	
(PBMNCs)	 from	 23	 αGal-	positive	 hDAF	 pigs	 with	 known	 lineage,	
selected	 to	 represent	a	broad	diversity	of	 swine	SLA-	I,	were	used	
as	 target	 cells.	 In	 the	1884	 cross-	match	 combinations,	 about	20%	
retained	antibody	reactivity	to	porcine	PBMNCs	after	anti-	Gal	an-
tibody	depletion.	When	the	serum	samples	were	stratified	for	PRA	
the	majority	of	this,	αGal-	independent	cross-	reactivity	was	present	
in	 serum	with	 PRAs	 >64%.	 Similar	 results	 were	 shown	 by	 Varela	
et al34	using	nontransgenic	pig	cells.	These	studies	concluded	 that	
human	sera	with	broad	panel	reactivity	(PRA	>64%)	can,	but	do	not	
always	exhibit	increased	cross-	reactivity	to	porcine	PBMNCs.
When	 allo-	sensitized	 waitlisted	 patient	 serum	 is	 progressively	
absorbed	with	RBC	and	porcine	platelets	 to	deplete	both	anti-	Gal	
and	anti-	SLA-	I,	it	is	evident	that	the	residual	αGal-	independent	an-
tibody	 reactivity	present	 in	 some	highly	 sensitized	patients	 reacts	
with	 swine	 SLA.	 Naziruddin	 et	al30	 demonstrated	 that	 affinity-	
purified	anti-	Gal	 antibody	binding	 to	pig	PBMNCs	was	effectively	
blocked	by	saturating	 levels	of	 the	αGal-	specific	 lectin	GSIB-	4	but	
that	antibody	reactivity	to	pig	PBMNCs	in	patients	with	medium	to	
high	PRA	was	αGal	 independent.	This	antibody	reactivity	was	also	
F IGURE  1 UNOS	data	showing	the	number	of	kidney	transplant	
candidates	on	the	waiting	list	and	the	breakout	of	patients	based	
on	calculated	panel-	reactive	antibody	(CPRA).	There	are	95	562	
candidates	for	kidney	transplantation	listed	in	January	2018.	The	
percentage	values	represent	the	total	percentage	for	each	CPRA	
grouping.	60%	of	candidates	have	a	CPRC	of	zero.	Within	the	
sensitized	patient	group	(n	=	40	128),	31%	(n	=	12	532)	have	a	
CPRA	>80%
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depleted by porcine platelets and reacted in Western blot to por-
cine	SLA-	1	heavy	chain.	Likewise,	platelet	depletion	was	shown	by	
Taylor	et	al31 to eliminate antibody reactivity to porcine cells in high 
PRA	patient	serum.	Importantly,	they	demonstrated	that	the	loss	of	
antibody	 binding	 after	 platelet	 absorption	was	 specific	 as	 porcine	
platelet	absorption	did	not	affect	allo-	specific	anti-	HLA	binding	to	
human	cells.	Similar	results	were	observed	in	a	unique	study	of	ex	
vivo	 porcine	 kidney	 perfusion	where	 both	 anti-	Gal	 and	 anti-	SLA-	I	
antibody	was	recovered	from	the	perfused	organ	of	some	but	not	
all sera plasma samples.32	These	absorption	studies	clearly	indicate	
that	some	high	PRA	patient	sera	exhibit	cross-	reactivity	to	porcine	
SLA-	I,	suggesting	that	at	 least	some	broadly	reactive	anti-	HLA	an-
tibody	 cross-	reacts	 to	 a	 restricted	number	of	 conserved	 serologic	
groups,	shared	between	human	and	porcine	MHC	class	I.	It	is	worth	
noting	 that	porcine	RBCs	express	 the	Gal	antigen,	but,	unappreci-
ated	at	the	time	of	these	studies,	also	express	additional	xenogeneic	
glycans.	The	depletion	of	additional	anti-	glycan	antibody	reactivity	
may	 have	 contributed	 to	 the	 success	 of	 detecting	 cross-	reactive	
anti-	SLA	antibody.
3.3 | Type IV studies
The	most	recent	studies	are	based	on	a	series	of	genetically	modi-
fied	pigs	which	progressively	eliminate	expression	of	the	known	
xenogeneic	 glycans.	 Tector	 and	 colleagues	 developed	 a	 series	
of	 pigs	 with	 mutations	 in	 GGTA-	1,	 eliminating	 αGal expression 
(single	 knockouts),	 GGTA-	1	 and	 cytidine	 monophosphate-	N-	
acetylneuraminic	acid	hydroxylase	(CMAH)	eliminating	both	αGal 
and	 the	 synthesis	 of	 Neu5Gc	 (double	 knockouts)	 and	 GGTA-	1,	
CMAH	and	B4GALNT2	eliminating	expression	of	αGal,	Neu5Gc-	
modified	glycans	and	SDa	glycans	(triple	knockout).16,38,39	Human	
serum	 shows	progressively	 less	 antibody	 reactivity	 to	PBMNCs	
from	these	pigs	with	approximately	60%	of	820	waitlisted	sam-
ples	negative	for	IgG	binding	and	30%	showing	only	background	
reactivity	 for	both	 IgM	and	 IgG	when	tested	on	triple	knockout	
cells.	Serum	samples	with	residual	antibody	reactivity	were	 fur-
ther	analyzed	by	absorption	with	porcine	RBCs	and	used	to	stain	
SLA-	I-	positive	and	SLA-	I-	negative	porcine	cells.	A	small	subset	of	
waitlisted	sera	 (9	of	119)	showed	clear	SLA-	I	 specific	 reactivity.	
A	similar	SLA-	I-	specific	analysis	of	RBC	absorbed	serum	from	pa-
tients	with	PRA	>80%	identified	13	of	22	with	SLA	class	I	specific	
IgG	and	4	of	17	with	SLA	class	I	specific	IgM.	When	antibody	from	
highly	 sensitized	 serum	 bound	 to	 human	 and	 porcine	 PBMNCs	
was	 recovered,	 single	 antigen	 bead	 analysis	 demonstrated	 that	
porcine-	specific	 IgG	 reactivity	 was	 limited	 to	 common	 epitope	
restricted	targets	present	on	a	 restricted	set	of	HLA-	I	antigens.	
These	 studies	 confirm	 earlier	 reports	 that	 some,	 but	 not	 all,	
highly	sensitized	patient	serum	contains	SLA-	I-	reactive	antibody.	
Importantly,	 these	 latest	 studies	 identify	 for	 the	 first	 time	 the	
MHC	cross-	reactive	groups	present	on	swine	SLA-	I	making	pos-
sible	further	genetic	modification	or	selection	to	eliminate	these	
alleles	and	minimize	antibody	reactivity	even	for	highly	sensitized	
patients.
4  | CONCLUSIONS
The	 prospects	 for	 clinical	 xenotransplantation	 have	 improved	 sig-
nificantly	due	 to	 recent	 increases	 in	preclinical	nonhuman	primate	
xenograft	 survival.	While	 the	 ideal	 donor	 organ	 is	 not	 universally	
defined	 and	may	 be	 different	 for	 different	 organs,	 it	 seems	 likely	
that	 donor	 organs	 with	 minimal	 antigenicity	 (GGTA1/CMAH/
B4GALNT2)	which	minimize	human	antibody	reactivity	will	make	a	
prominent	 contribution.	 Additional	 genetic	 modifications	 to	 regu-
late	 complement	 and	 coagulation	may	 also	 be	 used,	 but	 inclusion	
of	 these	 human	 transgenes	 should	 not	 affect	 antibody	 reactivity	
or tissue antigenicity. For most human sera and waitlisted patients 
with	zero	to	moderate	HLA	sensitization,	there	appears	to	be	mini-
mal	antibody	reactivity	to	these	triple	knockout	pig	cells	suggesting	
that	future	clinical	xenotransplantation	will	be	broadly	applicable	to	
most	patients.	Highly	sensitized	patients	 (PRA	>80%)	can	produce	
antibody	which	cross-	reacts	with	swine	SLA-	I,	but	this	is	not	an	obli-
gate	condition.	Whether	the	SLA-	I	cross-	reactive	antibody	in	highly	
sensitized	patients	has	immediate	impact	on	xenograft	survival	will	
depend	on	the	antibody	titer,	affinity	and	level	of	porcine	SLA-	I	ex-
pression.	Since	recent	studies	suggest	that	cross-	reactive	anti-	HLA	
antibody	is	directed	to	a	limited	set	of	HLA	antigens,	modern	genetic	
screening	and	modification	methods	may	be	used	to	select	for	pigs	
with	minimal	antibody	reactivity	even	for	highly	sensitized	patients.	
Patient	cross-	matching	is	a	corner	stone	of	successful	allotransplan-
tation	and	will	undoubtedly	play	no	 less	of	a	 role	 in	 future	clinical	
xenotransplantation.
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